Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Fennec Pharmaceuticals (FENC) Equity Average (2016 - 2025)

Fennec Pharmaceuticals' Equity Average history spans 15 years, with the latest figure at $15.5 million for Q4 2025.

  • For the quarter ending Q4 2025, Equity Average rose 380.54% year-over-year to $15.5 million, compared with a TTM value of $15.5 million through Dec 2025, up 380.54%, and an annual FY2025 reading of $14.8 million, up 269.2% over the prior year.
  • Equity Average for Q4 2025 was $15.5 million at Fennec Pharmaceuticals, up from -$6.0 million in the prior quarter.
  • The five-year high for Equity Average was $27.0 million in Q1 2021, with the low at -$11.1 million in Q4 2023.
  • Average Equity Average over 5 years is $2.8 million, with a median of -$3.3 million recorded in 2024.
  • Year-over-year, Equity Average crashed 9607.73% in 2023 and then soared 380.54% in 2025.
  • Tracing FENC's Equity Average over 5 years: stood at $20.6 million in 2021, then crashed by 99.44% to $116500.0 in 2022, then crashed by 9607.73% to -$11.1 million in 2023, then skyrocketed by 50.15% to -$5.5 million in 2024, then soared by 380.54% to $15.5 million in 2025.
  • Per Business Quant, the three most recent readings for FENC's Equity Average are $15.5 million (Q4 2025), -$6.0 million (Q3 2025), and -$6.7 million (Q2 2025).